Get the Stockscreener App
76.82
2.08%
-1.63
Ptc Therapeutics Inc stock is traded at $76.82, with a volume of 838.16K.
It is down -2.08% in the last 24 hours and down -8.99% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
See More
Previous Close:
$78.45
Open:
$79.33
24h Volume:
838.16K
Relative Volume:
0.48
Market Cap:
$6.37B
Revenue:
$1.73B
Net Income/Loss:
$682.64M
P/E Ratio:
9.9297
EPS:
7.7364
Net Cash Flow:
$411.18M
1W Performance:
-2.25%
1M Performance:
-8.99%
6M Performance:
+2.09%
1Y Performance:
+65.85%
1-Day Range:
$76.59
$79.40
1-Week Range:
$76.59
$80.56
52-Week Range:
$43.17
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
76.82 | 6.37B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTCT|PTC Therapeutics Inc|Price:76.820|Chg%:-1.630 - TradingKey
PTCT5396017 Bond Profile — Key Metrics - TradingView
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Barclays Remains a Buy on PTC Therapeutics (PTCT) - The Globe and Mail
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
Reasons why investors should consider betting on PTC stock now - MSN
Form 4 PTC Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares By Investing.com - Investing.com South Africa
PTC Therapeutics schedules second-quarter 2026 results webcast conference call - Bitget
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares - Investing.com
PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes - Stock Titan
PTCT Maintained by Cantor FitzgeraldPrice Target Raised to $1 - GuruFocus
Cantor Fitzgerald raises PTC Therapeutics stock price target on Sephience outlook - Investing.com Canada
PTC Therapeutics Sets July 30 Webcast for Business Update - Stock Titan
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - Barchart.com
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130 - Moomoo
PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders - Sahm
Form 144 PTC THERAPEUTICS For: 14 July By Investing.com - Investing.com Nigeria
PTC THERAPEUTICS, INC. SEC Filing (Jul 14, 2026) - Stock Titan
PTC Therapeutics (PTCT) Q1 2025 earnings summary - Quartr
PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Form 4 PTC Therapeutics Inc For: 13 July By Investing.com - Investing.com South Africa
PTC Therapeutics chief technical ops officer sells $222,376 in shares - Investing.com UK
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock - Investing.com UK
PTC Therapeutics chief technical ops officer sells $222,376 in shares By Investing.com - Investing.com Nigeria
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale - Stock Titan
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $91 - Moomoo
PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus - simplywall.st
PTC Therapeutics Inc (PTCT) - MSN
PTC Therapeutics (PTCT) Q3 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
PTC Therapeutics (PTCT) Q2 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance
Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions? - Yahoo Finance
PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Reasons Why Investors Should Consider Betting on PTC Stock Now - Yahoo Finance
PTCT (NASDAQ: PTCT) affiliate sale notice — Form 144 - Stock Titan
Form 144 PTC THERAPEUTICS For: 9 July By Investing.com - Investing.com South Africa
Stocks Look Shaky, But This Sector is Booming (Biotech) - Yahoo Finance
[144] PTC THERAPEUTICS, INC. SEC Filing - Stock Titan
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):